The Study
ILI was defi ned as fever >38.5°C and cough plus >1 of the following: sore throat, headache, and myalgia. Severe infl uenza was defi ned as any case confi rmed by reverse transcription PCR in a hospitalized person. The National Ministry of Health provided oseltavimir to every patient >5 years of age who had ILI. Approximately 80% of ILI cases corresponded to pandemic (H1N1) 2009 confi rmed by PCR in a pilot study.
All fatal cases included in the analysis occurred in persons whose deaths were directly attributable to infl uenza. Demographic data, clinical features, concurrent conditions, and number of consultations before hospitalization were recorded (3).
Denominators used for determining overall incidence rates and incidence rates by age group were based on the national census of 2002. Denominators used for determining rates for hospitalized case-patients and case-fatality rates (CFRs) were 80% of ILI cases reported to the Ministry of Health during the study. We conducted statistical analysis by using SPSS version 13.0 (SPSS Inc., Chicago, IL, USA) and Epi Info version 6 (Centers for Disease Control and Prevention, Atlanta, GA, USA).
During May 19-August 3, 2009, a total of 342,588 ILI cases were reported. Median age of case-patients was 20.4 years (range <1-109 years). The overall attack rates were 1.2% for pandemic (H1N1) 2009 and 0.4% for persons >60 years of age. During the same period, 651,416 treatments with oseltamivir were reported. Treatment data indicated that the attack rate was 4%.
A total of 1,585 persons confi rmed to have ILI were hospitalized. Median age was 33 years (range 11 days-94 years), and 52% were women. Overall rate of hospitalization was 9.4/100,000 persons. Case-hospitalization rate was 0.6% (3.5% for persons >60 years of age and 1.6% for children <5 years of age) ( Figure 1 ). Pneumonia was the most common diagnosis at admission (77.3%). Underlying diseases were present in 560 (56.6%) of 989 case-patients, and 217 (22%) had >2 concurrent conditions. A total of 130 hospitalized patients died (overall mortality rate 0.79/100,000 persons). Among these patients were 117 who died during the study period. Median age was 47 years (range 4 months-89 years) for persons who died and 30 years (range <1-94 years) for persons who survived (p<0.0001). Forty-seven percent of patients who died were >49 years of age. CFR was 0.04%: the highest rate was for patients >60 years of age (0.44%; p<0.0000001), followed by persons 15-59 years of age (0.045%). CFR was 0.02% for children <5 years of age and 0.008% for children 5-14 years of age ( Figure 2 ). Fifty percent of all deaths were caused by severe respiratory failure.
Age was a risk factor for severe infl uenza and death. Patients >60 years of age and <5 years of age were at a higher risk for severe disease, and patients >60 years of age were at a higher risk for death. At least 1 concurrent condition was identifi ed as a risk factor for death from pandemic (H1N1) 2009. Eighty-four (87.5%) of 96 patients who died and 485 (54.3%) of 893 of patients who survived had an underlying disease (odds ratio 5.89, 95% confi dence interval 3.08-11.52; p<0.00001). A concurrent condition was a risk only for persons 15-49 years of age (Table) .
Mean time from onset of symptoms to hospitalization was 4.3 days (range 0-20 days) for persons who died and 3.6 days (range 0-20 days) for persons who survived (p = 0.03). Median time from onset of symptoms to beginning of treatment with oseltamivir was 3.0 days for persons who died and for those who survived.
Conclusions
The strength of this study was inclusion of nearly all patients with confi rmed severe pandemic (H1N1) 2009 in Chile because of timely implementation of a national notifi cation system. The population studied included 97% of hospitalized patients with pandemic (H1N1) 2009. Differences in attack rate (1.2% by reporting of ILI cases and 4% by amount of oseltamivir provided) might be explained by the fact that not all ILI cases were captured (≈20% were lost because of underreporting) by the notifi cation system and oseltamivir was prescribed to persons with illness not included in the ILI case defi nition. We demonstrated in a pilot study that ≈60%-70% of oseltamivir used complied with the case defi nition for ILI.
The fi rst wave of pandemic (H1N1) 2009 in Chile showed the highest incidence rate in children 5-14 years of age; persons ≥60 years of age were least affected (2). However, our study identifi ed persons ≥60 years of age as at greatest risk for severe respiratory disease and death, despite the lower incidence rates. During the infl uenza pandemic, risk for illness in this age group was low but risk for severe disease and death was higher than in the other groups, independent of underlying diseases. This fi nding differs from results of a study in California, USA, in which persons >60 years of age did not have a high hospitalization rate (4). Our fi nding is consistent with those of a report on seasonal infl uenza in which risk for severe infection and hospitalization was highest for elderly persons (5) .
Before April 2009, infl uenza was rarely reported as the cause of death in Chile. Therefore, only CFRs for severe respiratory infection are available for comparison. The CFRs for patients >65 years during winter 2009 was similar to that during previous winters. We conclude that elderly persons' risk for a severe outcome during pandemic (H1N1) 2009 did not exceed this risk for a severe outcome during seasonal infl uenza. Previous reports have documented increased risk for severe outcomes in younger persons during pandemic (H1N1) 2009 and the absence of increased risk for disease severity among elderly persons (4, 6, 7) . On the basis of these fi ndings, some institutions made policy decisions to exclude anyone >65 years of age without concurrent conditions from satisfying recommendations for use of vaccine against pandemic (H1N1) 2009 because of absence of identifi ed increased risk for infection. Our study indicates an age >60 is the greatest risk factor for a severe outcome during pandemic (H1N1) 2009 and seasonal infl uenza.
Delay in medical care was another risk factor for death in this study. The number of consultations before admission did not differ between the groups, suggesting that patients who died sought medical care later than patients who survived. Thus, timely medical consultation affected patient outcome.
This study indicates that an age ≥60 years was the greatest risk for death associated with pandemic (H1N1) 2009 infl uenza, similar to that for seasonal infl uenza. These results can be used for future planning strategies for infl uenza, strengthening the need for infl uenza vaccination, opportune medical evaluation, and timely therapy specifi c for this age group. The opinions expressed by authors contributing to this journal do not necessarily refl ect the opinions of the Centers for Disease Control and Prevention or the institutions with which the authors are affi liated.
